Takeda Pharmaceutical Company Limited

Matsushita Electric Industrial Co., Ltd.

Panasonic Corporation

Canon Kabushiki Kaisha

Masato Yoshida

Yuriko Kaneko

Nobuki Sakauchi

Hideaki Kiryu

Kiyoshi Takahashi

Terufumi Takagi

Yusuke Sasaki

Yusuke Tominari

Takuya Ishii

Mamoru Takeda

Masaki Seto

Tsuneo Yasuma

Albert Charles Gyorkos

Hiroyuki Kimura

Mikio Motomori

Kazuaki Takami

Christopher Peter Corrette

Akito Shibuya

Zenyu Shiokawa

Tony Gibson

Takatoshi Yogo

Takayuki Murase

Akira Mori

Hiroyuki Nagamiya

Masahiro Kawase

Scott Alan Pratt

Shigenori Arai

Masahiro Yamamoto

Satoshi Sasaki

Makoto Horiuchi

Hideo Suzuki

Tsuneo Oda

Kazuhito Kimura

Takashi Ryu

Norihito Tokunaga

Shinichi Imamura

Minoru Ozasa

Hideyuki Kihara

Takaharu Hirayama

Ayumu Sato

Shuji Kitamura

Kazuyoshi Aso

Yoshitaka Kurimoto

Yasuhiro Hirata

Masanori Okaniwa

Hirohisa Tanabe

Shogo Marui

Tomokazu Kusumoto

Yuji Ishichi

Tomoya Shigemi

Moriteru Asano

Hiroshi Nagabukuro

Hyun Bin Kang

Yasuhisa Kohara

Naoki Iwamura

Ryo Minamihata

Shunsuke Ono

Jun-ichiro Hara

Yusuke Ohba

Takashi Ichikawa

Hye Sun Jeon

Cheolhwan Yoon

Yoshihito Kawakami

Chul Yun Rhim

Takashi Motoyaji

Tomohiko Suzaki

Kwang Ok Kim

Gil Nam Lee

Takahisa Matsuda

Haruhiko Kuno

Reiko Saikawa

Yuuichi Okabe

Shigemitsu Imai

Ryou Watabe

Kazuhisa Takada

Provided is a liquid ejection apparatus including an ink cartridge including a first ink storage section which stores ink; an ink tank including a second ink storage section which is connected to the ink cartridge and supplied with ink from the ink cartridge; and a detection unit including a light emitting section which emits detection light and a light receiving section which receives the detection light, in which the ink cartridge includes a first protrusion in communication with the first ink storage section, the ink tank includes a recess and a second protrusion in communication with the second ink storage section, the light emitting section and the light receiving section are arranged in the recess, and the first protrusion and the second protrusion are arranged between the light emitting section and the light receiving section.

Liquid ejection apparatus

The present invention provides a medicament for preventing or treating heart failure. More specifically, the present invention provides a medicament for preventing or treating heart failure, comprising a compound selected from the group consisting of (5R)&#x2014;N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)&#x2014;N-[1-ethyl-1-(4-methoxyphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)&#x2014;N-[1-ethyl-1-(4-ethylphenyl)propyl]-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and salts thereof.

Medicament for treating heart failure

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic amide compound

The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compound

Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.

There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted 5- to 7-membered heterocyclic ring; Xis CR, CRR, N or NR; Xis N or NR; Y is C, CRor N, Z is CR, CRR, N or NR; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; andis a single bond or a double bond; R, R, R, R, R, R, Rand Rare independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7-membered ring; Q is C, CRor N; R, R, R, Rand Rare independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X, R, R, Y and Xin formula (II) and (III) as before.

Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

The present invention aims to provide an iminopyridine derivative compound having an &#x3b1;adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like. The present invention provides a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Iminopyridine derivatives and use thereof

Provided are an iminopyridine derivative having a selective &#x3b1;adrenergic receptor antagonistic action and useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like, and a screening method for a compound having an &#x3b1;adrenergic receptor antagonistic action. An &#x3b1;adrenergic receptor antagonist containing a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof, and a method of screening for an agent having an &#x3b1;adrenergic receptor antagonistic action for the prophylaxis or treatment of a lower urinary tract disease, which includes measuring the bladder smooth muscle tension of rats with bladder outlet obstruction.

Iminopyridine derivative and use thereof

Iminopyridine derivatives and uses thereof

There is provided a charging apparatus that, even when an AC adapter is connected and there is heavy load, makes it possible to reduce heat produced due to the power loss of a control transistor, reduce cost and area for implementation, and improve safety. Charging apparatushas: P-channel MOS transistors Mand Mthat control charging current; current detecting resistance Rs that is connected to current output terminals of P-channel MOS transistors Mand Mand detects the charging current; switchthat is arranged on a path that bypasses current detecting resistance Rs; and loadthat receives power supply from batterywithout involving current detecting resistance Rs when switchis closed. Current difference amplifieramplifies the detected voltage of current detecting resistance Rs, comparatorcompares the output voltage of current difference amplifierwith the reference voltage, and thereby, when current flowing into batteryis equal to or less than a predetermined value, switchis closed and current detecting resistance Rs is short-circuited.

Charging apparatus

An interface detecting circuit and interface detecting method are provided, whereby operations can be carried out depending on peripheral devices connected to USB terminals, and whereby the system can be simplified and software load can be reduced. A pull-down resistor is connected to an ID terminal of a Mini-A receptacle of a peripheral device, the voltage generated by the pull-down resistor, which is pulled down by the ID terminal of the Mini-A receptacle of the peripheral device, and a pull-up resistor, which is pulled up by the ID terminal of a Mini-B receptacle of a device, is detected in an analog fashion, using a detecting section comprised of comparators, and, via a logic section, a logic output is subjected to noise cancellation in a filter section and is memorized in a register section. The operations of other devices are determined according to the states memorized in the register section.

Interface detecting circuit and interface detecting method

Growing community of inventors

Kanagawa, Japan

Masato Yoshida